Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Bioblast Pharma
ORPN

Buy Bioblast Pharma (ORPN) Stock

ORPN
See ORPN stock price and Buy/Sell Bioblast Pharma with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
ORPN

Bioblast Pharma (ORPN)

—

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Bioblast Pharma (ORPN)

Enlivex Therapeutics Ltd. is a clinical stage macrophage reprogramming immunotherapy company, which develops Allocetra,a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.
Market Cap
$93.89M
1 Year High
$13.95
Volume
27.48k
1 Year Low
$3.65
Price to Earnings Ratio
—
Open
$5.11
Dividend Rate
—
High
$5.21
Dividend Yield
—
Low
$5.01

Community

People who own or watch ORPN stock

Bioblast Pharma stock rating

What analysts recommend for ORPN stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
1

Bioblast Pharma price target

What analysts think ORPN will be worth
Low $3.65
High $20
Current $5.11
Target $20

Bioblast Pharma earnings

The value each share was expected to gain vs. the value that each share actually gained
0
-0.15
-0.3
-0.45
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Expected EPS
Q3 2022
-$0.37
Actual EPS
Q3 2022
–

Buy Bioblast Pharma (ORPN) Stock

ORPN
See ORPN stock price and Buy/Sell Bioblast Pharma with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch ORPN stock
  • Phoenixbird1 avatar
  • MobyBear avatar
  • markb3847 avatar
  • ricofly3 avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.

View Full Disclosures